Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term repeat-dose open-label phase 3 study of INI101 for moderate to severe glabellar lines
CTR20252233Phase 3Active
- Sponsor
- Inibio
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of INI101 in glabellar furrowing, sponsored by Inibio. Primary endpoint: Adverse drug reaction incidence. Started Jun 2025; status: active.
02
Drugs
INI101
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on CTR20252233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252233.